PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Oral - Market size and forecast 2018-2023 Intravenous - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS The advent of gene therapy to control ventricular rate in AF Technological advances enabling the early detection of cardiac arrhythmias Growing R&D efforts by vendors PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bayer AG Eli Lilly and Co. GlaxoSmithKline Plc Pfizer Inc. Sanofi PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Application - Market share 2018-2023 (%) Exhibit 19: Comparison by application Exhibit 20: Oral - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Oral - Year-over-year growth 2019-2023 (%) Exhibit 22: Intravenous - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Intravenous - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by application Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Diagnostic methods Exhibit 43: Side-effects of cardiac arrhythmias therapeutics Exhibit 44: Substitute products to cardiac arrhythmias therapeutics Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Bayer AG - Vendor overview Exhibit 52: Bayer AG - Business segments Exhibit 53: Bayer AG - Organizational developments Exhibit 54: Bayer AG - Geographic focus Exhibit 55: Bayer AG - Segment focus Exhibit 56: Bayer AG - Key offerings Exhibit 57: Bayer AG - Key customers Exhibit 58: Eli Lilly and Co. - Vendor overview Exhibit 59: Eli Lilly and Co. - Business segments Exhibit 60: Eli Lilly and Co. - Organizational developments Exhibit 61: Eli Lilly and Co. - Geographic focus Exhibit 62: Eli Lilly and Co. - Segment focus Exhibit 63: Eli Lilly and Co. - Key offerings Exhibit 64: Eli Lilly and Co. - Key customers Exhibit 65: GlaxoSmithKline Plc - Vendor overview Exhibit 66: GlaxoSmithKline Plc - Business segments Exhibit 67: GlaxoSmithKline Plc - Organizational developments Exhibit 68: GlaxoSmithKline Plc - Geographic focus Exhibit 69: GlaxoSmithKline Plc - Segment focus Exhibit 70: GlaxoSmithKline Plc - Key offerings Exhibit 71: GlaxoSmithKline Plc - Key customers Exhibit 72: Pfizer Inc. - Vendor overview Exhibit 73: Pfizer Inc. - Business segments Exhibit 74: Pfizer Inc. - Organizational developments Exhibit 75: Pfizer Inc. - Geographic focus Exhibit 76: Pfizer Inc. - Segment focus Exhibit 77: Pfizer Inc. - Key offerings Exhibit 78: Pfizer Inc. - Key customers Exhibit 79: Sanofi - Vendor overview Exhibit 80: Sanofi - Business segments Exhibit 81: Sanofi - Organizational developments Exhibit 82: Sanofi - Geographic focus Exhibit 83: Sanofi - Segment focus Exhibit 84: Sanofi - Key offerings Exhibit 85: Sanofi - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of market positioning of vendors    

Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.